Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 943-951

  Ezat, Sharifa W P ^a   Aljunid, Syed ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b United Nations University   (Malaysia)

Author keywords

Cervical cancer; Cost effectiveness; HPV vaccinations; Pap smear screening; Quality of life

Indexed keywords

EID: 78650695711     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Amrizal MN, Rohaizat Y, Zafar A, et al (2005). Case-mix costing in Universiti Kebangsaan Malaysia Hospital. A top down approach: cost analysis for cardiology cases. Malaysian J Public Hlth, 5, 33-44.
2. Annual Report (2006). Ministry of Health, Malaysia.
3. Ault KA (2006). Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol, 14, 1-5.
4. Centers for Disease Control, Prevention (1999). Prevention of genital HPV infection and sequelae: Report of an external consultants' meeting. Georgia US: Division of STD Prevention CDC.
5. Clifford GM, Gallus S, Herrero R, et al (2005). Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-9.
6. Elbasha EH, Dasbach EJ, Insigna RP (2007). Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis, 13, 28-40.
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med, 356, 1928-43.
8. Goldie SJ, Kohli M, Grima D, et al (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst, 96, 604-15.
9. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al (2005). Cost-effectiveness of cervical cancer screening in five developing countries. N Eng J Med, 353, 2158-69.
10. Harper DM, Franco EL, Wheeler CM, et al (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet, 15, 1247-55.
11. Jit M, Choi YH, Edmunds WJ (2008). Economic evaluation of human papillomavirus vaccination in the United Kingdom. Bri Med J, 337, 12.
12. Joura EA, Leodolter S, Hernandez-Avilla M, et al (2007). Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet, 369, 1693-702.
13. Kohli M, Ferko N, Martin A, et al (2007). Estimating the long term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Bri J Cancer, 96, 143-50.
14. Koutsky LA, Ault KA, Wheeler CM, et al (2002). A controlled trial of a human papillomavirus type 16 vaccine. N Eng J Med, 347, 1645-51.
15. Koutsky LA (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med, 356, 1915-27.
16. Markowitz LE, Dunne EF, Saraiya M, et al (2007). Quadrivalent Human Papillomavirus vaccine. recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 56, 1-23.
17. National Cancer Registry (2006). Fourth report of the national cancer registry cancer incidence in Malaysia. Ministry of Health, Malaysia.
18. Nik Ibrahim NS (2005). Cost effectiveness of pap smear screening in cervical cancer screening. Doctorate thesis, universiti Kebangsaan Malaysia.
19. Othman NH, Devi BCR, Halimah Y (2009). Cervical cancer screening: patients' understanding in major hospitals in Malaysia. Asian Pac J Cancer Prev, 10, 569-74.
20. Rousseau MC, Pereira JS, Prado JSM, et al (2001). Cervical co- infection with human papillomavirus types as a predictor of acquisition and persistence of HPV infection. J Infecti Dis, 184, 1508-17.
21. Sanders GD, Taira AV (2003). Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis, 9, 37-48.
22. Sharifa Ezat WP, Syed Aljunid (2010). Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev, 11, 79-90.
23. Sharifa Ezat WP, Syed MA, Paul N, et al (2009). Quality of life among preinvasive and invasive cervical cancer in Malaysia. ASEAN J Psychiatry, 10, 115-26.
24. Sharifa Ezat WP, Norin R, Sharifah Noor Akmal SH, et al (2009). Prevalence of human papillomavirus in cervical cancer. Article in Press, Med & Hlth J.
25. Siti Haniza M (2007). Economic evaluation of immunization program against poliomyelitis in Malaysia: oral polio vaccine versus inactivated polio vaccine. PhD Thesis, Universiti Kebangsaan Malaysia.
26. Skinner SR, Garland SM, Stanley MA, et al (2008). Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust, 188, 238-42.
27. Smith JS, Melendy A, Rana RK, et al (2008). Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Hlth, 43, 5-25.
28. Taira AV, Neukermans CP, Sanders GD (2004). Evaluating human papillomavirus vaccination programs. Emerg Infect Dis, 10, 1915-23.
29. Villa LL, Costa RLR, Petta CA, et al (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5-years of follow up. Bri J Cancer, 95, 1459-66